PMID- 34368997
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 48
IP  - 11
DP  - 2021 Nov
TI  - Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil 
      counts in psoriasis patients.
PG  - 1739-1744
LID - 10.1111/1346-8138.16102 [doi]
AB  - Psoriasis is a chronic disease centered on tumor necrosis factor (TNF), 
      interleukin (IL)-23, and IL-17 axis. While psoriasis patients benefit from 
      biologics targeting TNF, IL-17s, and IL-23 nowadays, suppression of these 
      molecules could modulate the balances of immune systems. However, the incidence 
      of autoimmune disease and T-helper 2 reaction during biologic treatments for 
      psoriasis patients is not well documented. We retrospectively examined 
      antinuclear antibody (ANA), eosinophil counts, and immunoglobulin E (IgE) levels 
      for psoriasis patients who underwent biologic treatments in our dermatology 
      clinic from June 10, 2010 to January 29, 2020. A cumulative total of 199 biologic 
      treatments were performed for a total of 128 psoriasis patients. Compared to the 
      non-biologic group of 109 psoriasis patients who received non-biologic treatment, 
      patients treated with infliximab showed more incidents of high ANA (14%, 
      p = 0.039) and high eosinophils (14%, p = 0.021). The use of brodalumab increased 
      incidents of high eosinophils (21%, p = 0.005) but did not affect increase in ANA 
      and IgE. The increase in high IgE level was observed significantly more during 
      the use of risankizumab (15%, p = 0.011). Methotrexate was the most frequently 
      used concomitant systemic treatment, but methotrexate did not affect ANA, 
      eosinophil counts, and IgE levels. Since the biologics for psoriasis treatment 
      modulate the balance of T-helper cells, careful observation is required to detect 
      unexpected changes of systemic immune conditions under biologic treatments.
CI  - (c) 2021 Japanese Dermatological Association.
FAU - Sugiura, Riichiro
AU  - Sugiura R
AUID- ORCID: 0000-0002-5593-3276
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
AD  - Department of Dermatology, National Defense Medical College, Tokorozawa, Japan.
FAU - Terui, Hitoshi
AU  - Terui H
AUID- ORCID: 0000-0002-7598-2833
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Shimada-Omori, Ryoko
AU  - Shimada-Omori R
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Yamazaki, Emi
AU  - Yamazaki E
AUID- ORCID: 0000-0002-1189-3962
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Tsuchiyama, Kenichiro
AU  - Tsuchiyama K
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Takahashi, Toshiya
AU  - Takahashi T
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Aiba, Setsuya
AU  - Aiba S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Yamasaki, Kenshi
AU  - Yamasaki K
AUID- ORCID: 0000-0002-5495-4956
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20210808
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Biological Products)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antibodies, Antinuclear
MH  - *Biological Products/therapeutic use
MH  - Eosinophils
MH  - Humans
MH  - Immunoglobulin E
MH  - *Psoriasis/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - antinuclear antibody
OT  - biologics
OT  - eosinophil
OT  - immunoglobulin E
OT  - psoriasis
EDAT- 2021/08/10 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/08/09 07:03
PHST- 2021/07/07 00:00 [revised]
PHST- 2021/04/04 00:00 [received]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2021/08/09 07:03 [entrez]
AID - 10.1111/1346-8138.16102 [doi]
PST - ppublish
SO  - J Dermatol. 2021 Nov;48(11):1739-1744. doi: 10.1111/1346-8138.16102. Epub 2021 
      Aug 8.